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Glucocorticoids (GCs)' are well established as modulaters of the immune and
inflammatory responses in man and in animal models . Most studies of the effects
of GCs on the immune responses have demonstrated that GCs are generally
immunosuppressive . The suppressive effects include GC-induced rodent thymo-
cyte lysis (1), inhibition ofantigen- and mitogen-inducedlymphocyte proliferation
(2-4), inhibition of production of and response to lymphokines (5, 6), and
inhibition of NK activity (7) . Recent studies also report that GC inhibits IL-2-R
gene expression (8) . Conflicting data have been published concerning the effect
of GCs on B lymphocytes. The production of polyclonal Ig is significantly
enhanced in the presence ofGCsin vitro (9-11) . The magnitudeofthe enhancing
effect was similar to that observed with other polyclonal B cell activators such as
PWM. Since this effect by GCs did not require proliferation, GCs might accel-
erate B cell maturation and differentiation . However, despite extensive investi-
gation, the precise mechanism of these contrasting effects (inhibitory and en-
hancing) ofGC remains to be clarified .
IL-1, a hormone-like polypeptide, functions as a fundamental mediator of
immune and inflammatory responses . Although IL-1 has been defined as a
thymocyte comitogenic factor (12), it has become evident that IL-1 exhibits a
diverse range of biological activities . These include augmentation of B lympho-
cyte proliferation (13)andantibody production (14), fibroblast proliferation (15),
acute-phase protein-inducing activity (16), prostaglandin-inducing activity (17),
and endogenous pyrogen activity (18) .
GCs have been reported to suppress both the production and effects of IL-1 .
GCs suppress IL-1 production by LPS-stimulated mouse peritoneal macrophages
(19, 20) . Recently we have extended this observation and shown that GC inhibits
the production of both IL-la and IL-1,B by LPS-stimulated human monocytes
(Lew, W., JJ . Oppenheim, and K. Matsushima, submitted for publication) .
Consequently, this suppressive effect of GC on IL-1 production may contribute
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' Abbreviationsused in thispaper.
￿
AET, 2-aminoethylisothiouromium bromide ; D-PBS, Dulbecco's
phosphate buffered saline ; GC, glucocorticoids ; LGL, large granular lymphocytes ; SRBC, sheep
erythrocytes .
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to the immunosuppressive and the antiinflammatory effect of GC . The effects
of IL-1 are also downregulated by GC since GC suppresses the thymocyte
comitogenic activity of IL-1 (20) . We also observed that GC suppresses IL-1-
induced proliferation ofhuman dermal fibroblasts .
Dower et al . (21) have recently reported the existence of specific receptors for
IL-1 on a variety of both human and murine cell types . We have also demon-
strated high-affinity receptors for IL-1 on an EBV-transformed human B lym-
phocyte cell line that binds IL-la and IL-1,8 equally well (22) . Since GC down-
regulates the effects of IL-1, we speculated that this may be based on effects of
GC on the expression of receptors for IL-1 . Therefore we investigated the effect
of GC on IL-1-R expression of human PBMCs . Unexpectedly, our data reveal
that GC dramatically increased IL-1-R expression on PBMCs within several
hours without any loss in the binding affinity .
Materials and Methods
Reagents. Prednisolone, dexamethasone, cortexolone (17-hydroxy-l1-deoxycorticos-
terone), progesterone, 17#-estradiol, and testosterone were purchased from Sigma Chem-
ical Co . (St . Louis, MO). Cycloheximide and actinomycin D were also obtained from
Sigma Chemical Co . Human rIL-la was a generous gift from Dr .M . Yamada (Dainippon
Pharmaceutical Co ., Osaka, Japan) . Human rIL-1,B was a generous gift from Dr . Y . Hirai
(Otsuka Pharmaceutical Co ., Tokushima, Japan) .
Cell Cultures.
￿
PBMCs were obtained from PBLs isolated from healthy volunteers by
leukapheresis. Mononuclear cells were separated by centrifugation on a Ficoll-Hypaque
gradient . To separate T lymphocytes, PBMCs were mixed with 2-aminoethylisothiourom-
ium bromide (AET ; Sigma Chemical Co.)-treated sheep erythrocytes (SRBCs) for 1 h on
ice . The rosetting and nonrosetting cells were separated by Ficoll-Hypaque gradient
centrifugation . The SRBCs were removed from the rosetting cells by lysis with NH4Cl-
lysing buffer . The nonadherent rosetting population obtained by removal of plastic
adherent cells was demonstrated to consist of 92% Leu 4' and 5% Leu 11' cells as
determined by flow cytometry and will be referred to as "T cells" population . The
nonrosetting cells included B lymphocytes (12% Leu 12+), monocytes (71% Leu M3+),
large granular lymphocytes (LGLs ; 13% Leu I I'), and rosette-positive cells (<4%) and
will be referred to as "non-T cells ."
Largenumbers ofcells enriched in B lymphocytes can be obtained by using a technique
known as counter-current centrifugal elutriation . The "lymphocyte" fraction, which
consists ofsmall lymphocytes, and an "intermediate" monocyte fraction, which consists of
monocytes and large lymphocytes, were isolated from PBMCs by counter-current centrif-
ugal elutriation as described elsewhere (23). Subsequently, the cells in each fraction were
separated into T andB cell populations by two times AET-SRBC rosetting of lymphocytes .
The nonrosetting cells from the lymphocyte fraction was shown to consist of 65% Leu
12' and 4% Leu M3' cells and will be referred to as the "small B cells," and the cells from
intermediate monocyte fraction consisting of 58% Leu 12', 23% Leu M3', 22% Leu 11',
and 5% Leu 4' cells and will be referred to as the "large B cells." We chose not to use
surface Ig as a marker because anti-Ig (even Ffab]'2) reacts with both human B lympho-
cytes and monocytes .
LGLs were separated from PBMCs as previously described (24) . Briefly, PBMCs were
depleted of monocytes by adherence on a plastic surface and applied to a nylon wool
column, and the eluted cells were then fractionated on a seven-step discontinuous gradient
of Percoll (Pharmacia Fine Chemicals, Uppsala, Sweden) at concentrations between 40
and 60% . LGL-enriched preparations collected from the low-density fraction (fraction 2
and 3) were demonstrated to contain 75-80% Leu 11' cells.
A monocyte-enriched population was obtained by detaching adherent PBMCs from a
plastic surface, and comprised 82% Leu M3' cells . A human LGL cell line YT (25) was926
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maintained in RPMI 1640 (Cellgrow ; Mediatech, Washington, DC) supplemented with
10% FCS (HyClone Laboratories, Logan, UT), 2MM ofL-glutamine, 100 U/ml penicillin,
and 100 wg/ml streptomycin at 37°C in 5% C0 2 .
The cells were resuspended at a density of 5 X 10 5 cells/ml in RPMI 1640 medium
with 10% FCS . All cultures were performed at a final volume of 20 ml in 100 X 20-mm
culture dishes (model 3100 ; Costar, Data Packaging Corp ., Cambridge, MA). The cells
were incubated in a humidified atmosphere at 37°C with 5% C02 as described . The
various steroid hormones were dissolved in 95% ethanol and added to the culture media
to yield the indicated final concentration . An equivalent volume of ethanol was added to
control cultures . Cell viability after drug treatment was>95% by trypan blue dye exclusion
test.
Human dermal fibroblasts (CRL 1507 ; American Type Culture Collection, Rockville,
MD) weregrown in Eagle's MEM (Cellgrow ; Mediatech, Washington, DC) supplemented
with 10% FCS, 2MM L-glutamine, and antibiotics . Fibroblasts (5 X 105 cells) were plated
in 35-mm diam dishes (model 3506 ; Costar, Data Packaging Corp .) containing 2 ml of
medium . After 2 d, the medium was then replaced with 2 ml ofnew medium with steroid
hormones .
Preparation ofIodinated IL-la .
￿
Human rIL-la was labeled with 125 1 using the Bolton-
Hunter reagent as described previously (22) . Briefly, 4 ug of human rIL-la (2 X 107
U/mg) without carrier protein in 50 fcl of 0.1 M borate buffer, pH 8.5, was conjugated
to the 1 MCi of 1251-labeled Bolton-Hunter reagent (2,200 Ci/mmol ; monoiodinated ; New
England Nuclear, Boston, MA) (26) for 1 h on ice . After stopping the reaction with 0.5
ml of 0.05 M glycine in 0.1 M borate buffer, pH 8.5, 1211-IL- Ia was separated from free
iodine by chromatography on a Sephadex G-25 column (1 X 20 cm) equilibrated with
Dulbecco's PBS (D-PBS) and 10% glycerol . The biological activity of radiolabeled IL-la
was measured by a thymocyte comitogenic assay . The labeling efficiency of IL-la was
estimated by determining the number of units of unlabeled rIL-la required to inhibit
50% of the binding of the 1251-IL-la to YT cells . This indicated that IL-la contained 9.9
X 106cpm of
'251 per 1 kg ofIL-I . There was no significant loss ofthymocyte comitogenic
activity by 1251-labeled human rIL- la .
Receptor Binding Assay .
￿
After the treatment with steroid hormones, the cells were
harvested and washed twice with cold D-PBS, and resuspended with 0.2 ml of binding
medium (RPMI 1640 supplemented with 1 mg/ml BSA) in Eppendorf tubes. 1251-IL-la
(13 ng/ml) was incubated with cells in the presence and absence of unlabeled IL-la at a
concentration of 2 wg/ml. After incubation at 4°C for 1 h, the cells were centrifuged at
10,000 g for 10 s . The pellets were washed with 1 ml of cold binding medium and
centrifuged again . The cell suspensions with 0.2 ml of binding medium were layered onto
0.8 ml of 10% sucrose in D-PBS and centrifuged again at 10,000 g for 1 min . After
aspiration ofthe supernatants, the cell pellets in the tube were excised and the radioactivity
was counted in a gamma counter. Nonspecific binding, defined as the amount of '251-IL-
la bound to the cells in the presence of 2 jig/ml ofhuman rIL-la, was <2% of the total
radioactivity . In the case of human dermal fibroblasts, the cells in 35-mm dishes were
washed twice with cold D-PBS and were transferred to 0 .5 ml of binding medium
containing 1251-IL-la . After a 1-h incubation at 4°C, the cultures were rinsed four times
with cold D-PBS and solubilized in 0.5 ml of 0.1 N NaOH containing 2% Na 2C0 5 and
1% SDS . The total cell-associated radioactivity was determined by counting this volume
in a gamma counter.
Treatment with Metabolic Inhibitors .
￿
The cells were cultured with cycloheximide (10-5
M) or actinomycin D (10'6 M) in the presence of prednisolone (10-6 M) . After 6 h of
culture, the effects of metabolic inhibitors on the expression of IL-I-Rs were measured .
The viability of the treated cells was not changed as compared with the control cells.
Results
Kinetics and Affinity of '257-IL-la Binding to GC-treated PBMCs.
￿
The specific
binding of 12'1-IL-I a to cells increased rapidlyand maximal binding was reachedafter 1 h at 4 °C and remained stable for up to 3 h (data not shown) . In all
subsequent experiments, incubations were therefore carried out for 1 h. The
results in Fig. 1 illustrate the effect of prednisolone (10-6 M) on I25I-IL-la
binding to human PBMCs . Each bar represents the mean of the triplicate
measurements of the specific 1251-IL-la binding as assessed by incubation with
150-fold excess of unlabeled human rIL-la . The specific binding increased
rapidly with time after exposure to prednisolone ; the maximal effect occurred
after 6h of exposure, and by 48 h declined toward control levels . A dose of 13
ng I25I-IL-la, used in this experiment, was sufficient to saturate the binding
sites.
Scatchard plot analysis was performed using PBMCs treated with 10-s M
prednisolone for 6 h to determine whether the increased binding can be ac-
countedforby an increase in thenumber of high-affinityreceptors. As illustrated
in Fig . 2, treatment with prednisolone led to an increase in the number of
1251-
IL-la binding sites on PBMCs without any reduction in affinity . Receptor
numbers increased from 130 on control cells to 1,480 on prednisolone-treated
cells . When PBMCs were treated with 10-5M prednisolone,
￿
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FIGURE 1 .
￿
Time course of 1251-IL-la binding to GC-
treated PBMCs . The cells (107 PBMCs) were incu-
bated in culture media (RPMI 1640 with 10% FCS)
in the presence of prednisolone (10-s M) for the
period as indicated. Subsequently, cells were har-
vested and specific binding of `I-IL-la at 0.72 nM
ligand was determined as described in Materials and
Methods. Each bar represents themean (and indicated
SD)of triplicate measurements .
FIGURE 2 .
￿
Scatchard plot analysis of '251-IL-
1a binding to control and prednisolone-treated
PBMCs .The cells (107 PBMCs) were incubated
for 6 h in the presence or absence of 10`sM
prednisolone . Subsequently, the cells were in-
cubated with various dilutions of '"I-11--la to
determine the specific binding .928
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receptors were expressed. Kd values of 4.1 X 10-10 M and 2.6 X 10-10 M were
obtained for control and treated cells, respectively. Thus, prednisolone markedly
increased the expression of high affinity IL-1-R on PBMCs. Furthermore, as
shown on Fig. 3, the prednisolone-induced IL- 1-R on PBMCs are bound equally
well by IL-la and IL-If .
Effect of Various Steroids on Specific I25I-IL-l a Binding.
￿
Human PBMCs were
exposed to different doses of various steroid hormones over a physiological and
pharmacological concentration range (10-5-10-10 M) for 6 h. Fig. 4 demonstrates
the specific binding of '251-IL-1a to treated PBMCs. GCs increased IL-I a binding
in a dose-dependent manner, and maximal effects were obtained with 10-7 M
dexamethasone and 10-5-10-6 M prednisolone. We also evaluated the effect of
other types of steroid hormones. Progesterone, 17-#-estradiol, and testosterone
had no effect on ' 251-IL-1a binding to PBMCs. In addition, a mineralocorticoid,
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FIGURE 3.
￿
Competitive effect on the bindingof '26I-
IL-la to prednisolone-treated PBMCs of unlabeled
humanrIL-1aandIL-1 fl.Thecells(10' PBMCs) were
incubatedfor6 h in the presence of 10-6 Mpredniso-
lone. Subsequently, thecellswere incubated with
"6I-
IL-la in thepresence ofvarious concentrations of IL-
la or IL-10 to determine the inhibitable binding of
1251-IL-la.
FIGURE 4.
￿
Effect ofsteroids on spe-
cific "6I-IL-la binding on human
PBMCs. The cells(10' PBMCs) were
incubated in culture media in the
presence ofvaryingconcentrations of
steroids. After culture for 6 h at
37°C, specific binding of "6I-IL-la
was determined. Nonspecific bind-
ing, definedas theamount of'2'1-IL-
1aboundto the cells in thepresence
of 0.11 AM of human rIL-1a, was
subtracted from total bindingto yield
specific binding.aldosterone, did not have any effect on 125I-IL-la binding to PBMCs (data not
shown) . Thus the capacity to enhance the binding of I25I-IL-la to PBMCs
appeared to be limited to GC .
Induction of IL-1-R by GC Was Mediated by the Receptor for GC.
￿
To further
ensure that the induction of IL-1-R was due to the physiologic effect ofGC, the
competitive effectsofan analogue cortexolone(17-hydroxy-11-deoxycorticoster-
one) were evaluated. Although cortexolone itselfhad a minimal inducing effect
on IL-1-Rs on PBMCs, it acted as a competitive antagonist ofGC-induced IL-1-
R expression (Fig . 5) . The dose-dependent induction of 1251-IL-la binding to
GC-treated PBMCs was shifted to the right in the presence of 3 X 10-5 M
cortexolone . At this concentration, cortexolone blocked about half of the induc-
tion of IL-1-R by 10-6 M prednisolone (data not shown) . These data suggest that
the effect of GC on IL-1-R expression is dependent on the interaction of GC
with its own receptor.
Effect of Metabolic Inhibitors on GC-induced IL-1-R Expression.
￿
To elucidate
whether GC-induced IL-1-R expression required newly synthesized protein and
RNA, we analyzed the effects of metabolic inhibitors, namely cycloheximide and
actinomycin D on the induction process. PBMCs cultured with cycloheximide
(10-5 M) or actinomycin D (10-6 M) in addition to an active concentration of
prednisolone
(10-6 M) for 6 h, were not induced to express IL-1-R (Table I) .
Cycloheximide (10-5 M) and actinomycin D (10-6 M) inhibited ^-90% of net
protein synthesis andRNA synthesis ofnormal human PBMCs, respectively (data
not shown) . These metabolic inhibitors did not reduce cell viability over a 6-h
period . Thus the induction of IL-1-R expression in PBMCsby GC required both
protein andRNA synthesis .
Identification of Lymphocyte Subpopulations That Express IL-1-R .
￿
PBMCs were
fractionated into T cells, B cells, LGLs, and monocyte-enriched populations to
elucidate the subpopulation on which GC induced to express IL-1-R . Table II
represents the effect of GC on each subpopulation . The T cell-enriched popu-
lation (AET-SRBC rosette-positive) was induced to express only a small increase
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FIGURE 5 .
￿
Inhibition of GC effect
on IL-1 binding by cortexolone in
PBMCs . The cells (10' PBMCs) were
incubated for 6 h at 37°C with var-
ious concentrations of prednisolone
alone, various concentrations ofcor-
texolone alone, and various concen-
trations of prednisolone with 3 X
10-5M cortexolone . The cells were
sedimented and washed, and specific
' 25I-IL-Ia binding was performed as
described .930 INTERLEUKIN I RECEPTOR INDUCTION BY GLUCOCORTICOIDS
TABLE I
Effects ofMetabolic Inhibitors on theInduction ofIL-1-R by GC
Agents added
TheCells(10' PBMCs) were incubated with 10-5 M cicloheximide or 10-6
M actinomycin D in the presence or absence of 10- M prednisolone for
6 h. The data represents thetotal binding of '451-IL-la to the cells.
TABLE 1I
Effects of GC on the Induction ofIL-1-R on Various Cells Types
Each subpopulation of PBMCs (10' cells) was incubated with 10-6 M
prednisolone for 6 h. YT cells (4 x 106 cells) and human fibroblasts (at
confluent state in 35-mm dishes) were incubated with prednisolone (10-6
M) for 18 h. The cells were harvestedand the specific "5I-IL-la binding
wasdetermined as described.
in IL-1-R by prednisolone. On the other hand, the non-T cell population (AET-
SRBC rosette-negative) was induced to express IL-1-R by prednisolone to a
much greater extent than unfractionated PBMCs. Neither purified LGLs nor
monocyte-enriched populations were induced by GC to express IL-I-R . Pred-
nisolone induced a significant enhancement of IL-1-R expression only on PBMC
populationsenriched in smalland large B lymphocytes. In addition, when PBMCs
were first cultured in the presence of 10-6 Mprednisolone at 37'C for 6 h and
then fractionated into T cells and non-T cells by E rosette formation, 107 Tcells
and non-T cells specifically bound 425 ± 45 and 6,912 ± 198 cpm '251-IL-la,
respectively. These data suggest that high level of IL-1-R are induced by GC
predominantly on B lymphocytes.
Exp. Cells
Radioactivity
Without With prednisolone
prednisolone (10-6 M)
cpm ± SD/ 10' cells
A PBMC 31 ± 3 4,284 ± 395
T cells 4,± 1 19.5 ± 1.5
Non-Tcells 133 ± 29 19,340 ± 157
LGL 12 ± 3 81 ± 25
Monocytes 45 ± 1.0 30 ± 6
B Small Bcells 82 565f 32
Large B cells ND 4,262
C PMN 86 ± 20.7 79 ± 20.8
D Fibroblasts 417 ± 32.5 1,214± 92
YT cells 3,085 ± 148 4,206± 125
Predniso-
lone
(10-6 M)
Cyclohexi-
mide
(10-5 M)
Actinomy-
cin D
(10-6 M)
Radioactivity
cpm ± SD/10' cells
1 - - - 619±13
2 - + - 470 ± 28
3 - - + 198 ± 36
4 + - - 3,270.5 ± 184
5 + + - 724 ± 92
6 + - + 166.5±0.5AKAHOSHI ET AL.
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GCs also increased the binding of '251-IL-la to human dermal fibroblasts and
to a limited extent on YT cells as shown in Table II . Thus, these data indicate
that GCs are able to induce IL- 1-R expression on several cell types .
Discussion
GCs play a critical regulatory role in cell differentiation and in the physiological
response to stress . GCs may cause their diverse effects directly by modulating
intracellular enzyme systems of target cells or indirectly by regulating heterolo-
gous hormone receptor systems, which is the so-called "permissive" action (27) .
GC hormones have been shown to upregulate heterologous hormone and cyto-
kine receptors including those for ,B adrenalin (28), insulin (29), cholecystokinin
(30), and epidermal growth factor (31) as permissive actions .
In this study, we have shown that GC elevates the number of IL-1-R on human
PBMCs by >10-fold at 6 h of incubation . The high affinity of IL-1-R binding
remains unaltered after treatment with GC . The upregulation of IL-I-R levels
as assessed by the binding of 1251-IL-Ia is also confirmed by data showing
increases in the binding of ' 25I-IL-la to the receptors as detected by chemical
crosslinking (32) . The functional capacity of the GC-induced IL-1-R on PBMCs
was studied by evaluating induction of protein phosphorylation by IL-1 . Carrier-
free human rIL-la induced phosphorylation within 5 min of an acidic cytosolic
65-kD protein at serine residue in GC-treated PBMCs (32) . Furthermore, only
GC-treated human PBMCs responded to rIL-1 with increases in the number of
Ig-producing cells in reverse hemolytic plaque-forming cell assays . GC-induced
polyclonal B cell activation could be inhibited by monoclonal anti-IL-1,B (Tosata,
G ., T . Akahoshi, JJ . Oppenheim, and K . Matsushima, manuscript in prepara-
tion) . These data suggest that GC induces high-affinity IL-1-R that are functional
in increasing B cell Ig production .
The upregulation of IL-1-R level is specific for GC . This is supported by the
lack of effect of other steroid hormones . Maximal effects were obtained with
10-7 M dexamethasone and 10-6 M prednisolone . This 10-fold higher potency
of dexamethasone on the enhancement of '251-IL-la binding correlates with the
greater andinflammatory potencies of this GC (33) . The effect of GC on IL-1-R
expression is mediated via the interaction of GC with its own receptor . This is
supported by the inhibitory effect of cortexolone, the competitive antagonist for
GC, which can bind to the GC receptor but has no GC activity (34).
The finding that cycloheximide and actinomycin D abolished the increase in
the level of IL-1-R indicates that GC stimulate de novo synthesis of protein and
RNA for IL-1-R . A requirement for RNA and protein synthesis has been also
demonstrated in the regulation of insulin and epidermal growth factor receptors
by GC (29, 31) . However, whether GC directly regulates gene expression for IL-
1-R remains to be established by cloning of IL-1-R gene(s) .
A number of reports highlight the complex interactions between GC and IL-
1 . Woloski et al . (35) showed that IL-1 could stimulate a mouse pituitary tumor
cell line to secrete adrenocorticotropic hormone which is followed by an increase
in the serum cortisol level . GCs in turn havebeen shown to inhibit the production
of IL-1 by murine peritoneal MO (20) and human monocytes (Lew, W . JJ .
Oppenheim,and K . Matsushima, submitted for publication) . GC and IL-1 also932
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regulate each others' receptor expression. Hill et al. (36) reported that IL-1
could decrease the expression of GC receptors in murine hepatocytes. On the
other hand, we have shown upregulation of IL-1-R on several cell types by GC.
Overall these observations suggest that GC and IL-1 mutually regulate each
others' production and effects. The capacity of GC to upregulate IL-1-R suggests
that IL-1 and GC can interact in agonistic as well as in an antagonistic manner.
GCs induced only subsets containing B lymphocytes to express more IL-1-R .
Since it was impossible to obtain purified B cells in sufficient numbers, all the
other cell types present in PBMCs were carefully evaluated. The non-T cell
subset expressed more IL-1-R after GC treatment, whereas T cells, LGLs, and
monocyte populations could not be induced to express more IL-1-R. Only B
cell-enriched populations (58-65% Leu 12' cells) responded well to GC and
expressed more IL-1-R. In addition, only GC-treated PBMCs responded to IL-1
with increases in the Ig-producing cells. Consequently, these data suggest that B
lymphocytes are the predominant non-T cell type that can be induced by GC to
express IL-1-R. But, at present, we cannot negate the possibility that minor
subpopulations in PBMCs such as dendritic cells also express more IL-1-R after
GC treatment. The availability ofantibody against IL- 1-R should enable us more
precisely to identify the subpopulations that respond to GC with increased levels
of IL-1-R expression.
A number of studies have shown the lymphoid cell compartment to exhibit
heterogeneous responses to GC (37). T lymphocytes and monocytes are reported
to be sensitive to GCs, since GCs inhibit several functions of these cell types. GCs
suppress thymocyte comitogenic responses (2), antigen- and mitogen-induced T
cell proliferation (2-5), mixed lymphocyte reaction (38), and IL-2 production by
T cells (6). GCs also inhibit antigen presentation (39), tumor cytotoxicity (40),
and IL-1 production of monocytes (19, 20). This depression of monocyte and T
lymphocyte functions may account for the immunosuppressive activities of GC
on cell-mediated inflammatory responses.
On the other hand, B lymphocytes are reported to be extremely resistant to
GC. Several studies have shown biphagic effects of GC on serum Ig level and
specific antibody production in vivo. Administration of high dose of GC slightly
diminishes the total serum Ig levels (41). This effect is explained in part by
decreased Ig synthesis and increased protein catabolism. Some studies have
demonstrated the enhancement of specific antibody production in patients
treated with GC (42), but others have showed no effect of GC on specific
antibody responses (43, 44). Many studies have demonstrated that GC stimulates
dramatic increase in polyclonal Ig production by human PBMCs in vitro (9-11),
comparable to those obtained with PWM. This stimulation of B cells by GC was
reported to be dependent on both T cells and monocytes. These observations
suggest that humoral immune responses can be stimulated by GC.
Enhancement of IL-1 production during the course of immune responses and
inflammation is subsequently followed by an increase in serum cortisol levels.
This favors immune deviation with potentiation of humoral immune responses
at the expense of cellular immune responses. Thus, we hypothesize that GC-
induced increases in antibody production may be mediated by IL-1 stimulationAKAHOSHI ET AL .
￿
93 3
of B cells bearing more functional receptors for IL-1 . Studies in progress are
aimed at investigating this hypothesis .
Summary
The in vitro effect of glucocorticoids (GCs) on IL-1-R expression of human
PBMCs was investigated . Both physiological and pharmacological concentration
ranges of GC increased the specific binding of '25I-labeled human rIL-la to
PBMCs . This enhancement was specific for GC, since other steroid hormones,
such as progesterone, 17,8-estradiol, andtestosterone failed to elevate thebinding
of '25I-IL-la to PBMCs. The effect was time dependent with maximal effect
occurring 6 h after treatment and dose dependent with half-maximal effect
elicited by 100 nM prednisolone . Scatchard plot analysis indicated that ' 25I-IL-
la binding increased from -100 IL-1-R per cell to 2 X 105 receptors per cell
without a major change in affinity (Kd = 2.6 X 10-'o M) . The subpopulation of
PBMCs induced by GC to express higher levels of IL-1-R consisted predomi-
nantly ofB lymphocytes, but not T lymphocytes, large granular lymphocytes, or
monocytes . GCs also induced the expression o£ IL-1-R on some other cell types,
including normal human dermal fibroblasts and the human large granular
lymphocyte cell line YT . Since cycloheximide and actinomycin D inhibited the
induction of IL-1-R by GC, synthesis of both newRNA and protein seems to be
required for IL-1-R induction . This study presents the first evidence of upregu-
lation of the receptors for IL-1 by GC, and may account for the reported
enhancement of in vitro and in vivo humoral immune responses by GCs.
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